April 1, 2014 7:54 AM | 1 min read |
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
In a report published Tuesday, MLV & Co analyst Graig C. Suvannavejh downgraded the rating on
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
(NASDAQ: PRAN) from Buy to Hold, and lowered the price target from $11.00 to $3.00.In the report, MLV & Co noted, “In yet another setback to the Alzheimer's disease (AD) space, PRAN's PBT2 failed to hit the primary endpoint (EP) in the P2b IMAGINE trial for prodromal or mild AD. PBT2 did actually lower brain amyloid as measured by imaging; unfortunately, so did treatment (tx) with placebo (PBO). PRAN remains optimistic (describing the results as ‘uninformative'), but in our mind, prospects of successfully developing PBT2 for AD have lessened quite dramatically. As a result, we now lower to a Hold/$3 PT from Buy/$11. At $3, we have not completely written off PBT2 in AD; doing so would've lowered our DCF to $2.50 (the value we assign for PBT2 in Huntington disease). Last remaining hopes for PBT2 in AD likely now rest upon data from a current 12-mo. extension study, but that probably won't read out until 1H15.”Prana Biotechnology Limited closed on Monday at $2.80.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.